The wide array of inflammatory conditions that have shown improvement by PARP inhibition ranges from chronic diseases such as diabetic neuropathy and atherosclerosis to more acute events such as sunburn-related inflammation and cisplatin-induced kidney inflammation [48,49,50,51,52,53,54].